Navigation Links
New genes involved in acute lymphoblastic leukemia play fundamental role in prognosis of the disease

This release is available in Spanish.

The inactivity or "silence" of certain genes plays a fundamental role in the prognosis of acute lymphoblastic leukemia as well as in response to treatment, according to the results of research involving a team made up of specialists from the University Hospital of Navarra and the Center for Applied Medical Research at the same University of Navarra, as well as the Reina Sofa Hospital in Cordoba, Andalusia.

In concrete, the work confirmed that the inactivation of 13 microRNAs (a type of gene) by an epigenetic mechanism (capable of modulating the functions of the genetic code), is associated with higher mortality amongst patients with ALL. In total, the study involved 353 patients - 179 children and 174 adults - with acute lymphoblastic leukaemia). The results open up new therapeutic options on demonstrating the possibility of using these microRNAs as new targets in the treatment of this cancer illness. The conclusions of the research were recently published in the scientific journal with the greatest international impact in its speciality, the Journal of Clinical Oncology.

Involved in the research work was a team made up of specialists from the University Hospital of Navarra and the Centre for Applied Medical Research (CIMA) of the University of Navarra. Specialists from the Reina Sofa Hospital in Crdoba and the Institute of Human Genetics at the Schleswig-Holstein University Hospital, Kiel Campus in Germany also participated in the study and the publication of results.

It is notable that acute lymphoblastic leukaemia is the most common oncological illness amongst children. It makes up 25% of all cancers amongst paediatric patients and approximately 75% of cases of leukemia in infancy, although current survival rates in developed countries stand at about 75% of diagnosed patients.

Subgroup with worst prognosis

With this research a set of 13 microRNAs was identified which showed up as epigenetically regulated in 65% of the patients studied with acute lymphoblastic leukaemia, according to Doctor Prsper. Epigenetic regulation is the modulation of the genes expression that does not depend on changes in the sequence of the genetic code and the influence of which in cancer is increasingly being demonstrated. They are, thus, reversible changes in the DNA that manage to get the genes to be expressed or not (to be activated or silent) depending on external conditions.

In the subgroup of patients amongst which this set of genes appears as regulated, it was shown that, although these patients initially responded to treatment, they were the ones who with greater frequency subsequently suffered relapse, disimprove and present the worst prognosis and survival rates. These are the patients amongst whom the disease is much more resistant to treatment and amongst whom a silencing of the expression of the microRNAs is produced, according to the specialist.

Most efficacious pharmaceutical drugs

Given these result, Doctor Prsper concludes that epigenetic regulation plays a fundamental role in the development of this disease. Moreover, he points out, it would seem that the most recent pharmaceutical drugs, capable of producing epigenetic alterations, can be effective in 65% of patients who respond worst to conventional therapies for acute lymphoblastic leukaemia.


Contact: Oihane Lakar
Elhuyar Fundazioa

Related medicine news :

1. Angiogenesis linked to poor survival in patients with rare type of ovarian cancer
2. Penn study finds link between Parkinsons disease genes and manganese poisoning
3. Genesis Pharmaceuticals Enters Into Agreement to Purchase Hongrui Pharmaceuticals, and Acquire 22 New Traditional Chinese Medicines
4. Cardiogenesis Announces Successful Educational Symposium at Society of Thoracic Surgeons Meeting in San Francisco
5. In Kids, Genes May Affect Leukemia Treatment
6. Popular or Not? Your Genes May Help Decide
7. Common Genes Link Bipolar Disorder, Schizophrenia
8. UCSF Researchers Use New Tools to Move in on Cancer Susceptibility Genes
9. 9 Genes Are Linked to Alzheimers
10. What is the pathogenesis of C. jejuni-related disease?
11. Few DNA repair genes maintain association with cancer in field synopsis
Post Your Comments:
Related Image:
New genes involved in acute lymphoblastic leukemia play fundamental role in prognosis of the disease
(Date:11/25/2015)... ... November 25, 2015 , ... ... aggressive than those found on mammography, according to a study published online in ... cancers not seen on mammography may necessitate a change in treatment. , Breast ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... offering factory direct sauna parts and accessories. , Sauna accessories help improve the ... bather’s style and personality. From basic styles for the purist looking for simplicity ...
(Date:11/25/2015)... ... November 25, 2015 , ... According to an article ... being more and more widely heralded as a breakthrough for performing hernia repairs. The ... over traditional laparoscopic surgery is that it can greatly reduce the pain that a ...
(Date:11/25/2015)... ... 25, 2015 , ... The McHenry County law firm of Botto Gilbert ... Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the ... App (2d) 130884WC. , According to court documents, Adcock testified that on May 10, ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... decades of music, friendships, and learning in its 65th Anniversary Brillianteen Revue, scheduled ... 5-6. , For 65 years, Brillianteen has been a treasured tradition ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Therapeutic Drug Monitoring (TDM) Market: Supplier ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/26/2015)... 2015 ) ... "Radioimmunoassay Market by Type (Reagents & Kits, ... Clinical Diagnostic Labs), Application (Research, Clinical Diagnostics), ... report to their offering. --> ... of the "Radioimmunoassay Market by Type ...
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
Breaking Medicine Technology: